Fourth quarter 2025 Financial Highlights (all comparisons are with the fourth quarter of 2024)
- Revenues were
$19.8 million , a decrease of 68%, or$41.7 million , compared to$61.5 million . - Net loss was
$12.0 million , or$0.27 per diluted share, down from net income of$2.8 million , or$0.06 per diluted share. - Adjusted EBITDA(1) was
($8.4) million , down from$5.3 million .
2025 Financial Highlights (all comparisons are with the year ended
- Revenues were
$95.7 million , a decrease of 61%, or$147.6 million , compared to$243.3 million . - Net loss was
$49.4 million , or$1.13 per diluted share, down from net income of$15.5 million , or$0.35 per diluted share. - Adjusted EBITDA(1) was
($38.3) million , down from$21.3 million .
(1) A non-GAAP financial measure. See “Non-GAAP Financial Measures” for a description of the measure and a reconciliation to the applicable GAAP measure.
“Excluding a
In the Chemicals segment, we completed construction of a new methacrylate plant, enabling backward integration into a key raw material and positioning us as a market supplier. The plant became operational late in the fourth quarter and is now fully qualified. We expect meaningful revenue contributions beginning in 2026. We also advanced several growth projects, including customer-backed capacity expansions and a significant production line upgrade, with contributions to revenue and margins anticipated toward the end of 2026. Demand opportunities continue to expand, supported by reshoring trends and our value proposition as a centrally located, efficient custom chemical manufacturer.
The Biofuel segment faced significant headwinds in 2025 following the expiration of the blenders tax credit and initial uncertainty surrounding the IRA 45Z replacement. This led to a strategic inventory reduction in the first half of the year and a temporary production pause. However, the release of final 45Z guidance has provided much-needed regulatory clarity through 2029. With Renewable Volume Obligations (RVO) expected to rise in 2026 and 2027, we have resumed raw material procurement and initiated a gradual restart of production.
Looking ahead to 2026, we are increasingly optimistic about the Biodiesel segment, supported by improved regulatory clarity despite continued elevated input costs. While chemical market demand is expected to remain soft, we anticipate higher utilization of our new methacrylate unit and increased production as expansion projects come online. Following weather-related downtime in January, we expect improved operating performance throughout the year.
Finally, we will celebrate our 50th anniversary this year. Over five decades, we have supplied critical specialty chemistries to many of the world’s leading consumer goods and chemical companies. We value these long-standing partnerships and look forward to continued success in the years ahead.” said
1
2026 Cash Dividends
In the fourth quarter of 2025,
Financial Overview and Key Operating Metrics
Financial and operating metrics, which include non-GAAP financial measures (see “Non-GAAP Financial Measures” for additional information), include all dollar amounts in thousands, except per share amounts:
Certain Financial and Operating Metrics (Dollars in thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended | ||||||||||||||||
| Dollar | % | |||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||
| Revenue | $ | 19,842 | $ | 61,509 | $ | (41,667 | ) | (68 | )% | |||||||
| (Loss) income from operations | $ | (12,489 | ) | $ | 1,611 | $ | (14,100 | ) | NA | |||||||
| Net (loss) income | $ | (12,011 | ) | $ | 2,797 | $ | (14,808 | ) | NA | |||||||
| (Loss) earnings per common share: | ||||||||||||||||
| Basic | $ | (0.27 | ) | $ | 0.06 | $ | (0.33 | ) | NA | |||||||
| Diluted | $ | (0.27 | ) | $ | 0.06 | $ | (0.33 | ) | NA | |||||||
| Adjusted EBITDA | $ | (8,439 | ) | $ | 5,313 | $ | (13,752 | ) | NA | |||||||
| Year Ended | ||||||||||||||||
| Dollar | % | |||||||||||||||
| 2025 | 2024 | Change | Change | |||||||||||||
| Revenue | $ | 95,742 | $ | 243,339 | $ | (147,597 | ) | (61 | )% | |||||||
| (Loss) income from operations | $ | (52,990 | ) | $ | 6,372 | $ | (59,362 | ) | NA | |||||||
| Net (loss) income | $ | (49,397 | ) | $ | 15,503 | $ | (64,900 | ) | NA | |||||||
| (Loss) earnings per common share: | ||||||||||||||||
| Basic | $ | (1.13 | ) | $ | 0.35 | $ | (1.48 | ) | NA | |||||||
| Diluted | $ | (1.13 | ) | $ | 0.35 | $ | (1.48 | ) | NA | |||||||
| Adjusted EBITDA | $ | (38,317 | ) | $ | 21,317 | $ | (59,634 | ) | NA | |||||||
Financial and Business Summary
Sales Revenue Declined Due to Biofuel Segment Uncertainty
Our consolidated sales revenue dropped significantly in both the quarter and year ended
- The three-month period saw a
$41.7 million decrease compared to 2024. - The twelve-month period saw a
$147.6 million decrease compared to 2024.
This decline was primarily due to ongoing uncertainty surrounding the clean fuel production credit (“CFPC” or “IRA 45Z”), which, together with very challenging input pricing, had a significant negative impact on our biofuel segment.
Operational Changes and Cost Measures
As industry conditions began to show signs of improvement, we moved decisively to align our operations with the shifting market.
- Market Timing: Capitalizing on favorable feedstock costs, we successfully brought our biodiesel production line back online in December.
- We reinstated certain previously furloughed employees to quickly restart biodiesel production, while maintaining a focus on labor cost reduction.
Income from Operations
- Quarterly Income: Income from operations for the three months decreased by
$14.1 million . This was primarily due to the reduced production volume caused by CFPC uncertainty. Also contributing to the decrease was the change in the last-in, first-out (“LIFO”) inventory adjustment (a$5.6 decrease in gross profit this quarter compared to a$0.1 increase in the same quarter last year) and a$5.5 million benefit in the prior year quarter from amortization of deferred revenue from a chemical contract that ended. This customer continues to purchase product on a short-term arrangement. - Twelve-Month Income: Income from operations for the twelve months decreased by
$59.4 million . This was driven by the reduced production and higher spending on parts and contract labor for a plant turnaround and other asset support. Similar to the quarter, the twelve-month period was also impacted from the change in the LIFO inventory adjustment (a$1.7 decrease in gross profit this year compared to a$3.0 increase last year).
Capital Expenditures
Capital expenditures were
Cash and Cash Equivalents
Cash and cash equivalents totaled
About
2
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements deal with FutureFuel’s current plans, intentions, beliefs, and expectations, and statements of future economic performance. Statements containing such terms as “believe,” “do not believe,” “plan,” “expect,” “intend,” “estimate,” “anticipate,” and other phrases of similar meaning are considered to contain uncertainty and are forward-looking statements. In addition, from time-to-time
These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. Factors that might cause actual results to differ include, but are not limited to, those set forth under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in FutureFuel’s Form 10-K Annual Report for the year ended
Non-GAAP Financial Measures
In this press release,
Adjusted EBITDA allows FutureFuel’s chief operating decision makers to assess the performance and liquidity of FutureFuel’s business on a consolidated basis to assess the ability of its operating segments to produce operating cash flow to fund working capital needs, to fund capital expenditures, and to pay dividends. In particular,
A table included in this earnings release reconciles adjusted EBITDA with net income, the most directly comparable GAAP performance financial measure, and a table reconciles adjusted EBITDA with cash flows from operations, the most directly comparable GAAP liquidity financial measure.
3
Condensed Consolidated Balance Sheets (Dollars in thousands, except per share amounts) (Unaudited) | ||||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 51,316 | $ | 109,541 | ||||
| Accounts receivable, inclusive of the blenders' tax credit of | 9,405 | 21,896 | ||||||
| Inventory, net | 21,254 | 20,643 | ||||||
| Other current assets | 18,548 | 12,706 | ||||||
| Total current assets | 100,523 | 164,786 | ||||||
| Property, plant and equipment, net | 86,797 | 78,538 | ||||||
| Other assets | 4,922 | 4,367 | ||||||
| Total noncurrent assets | 91,719 | 82,905 | ||||||
| Total Assets | $ | 192,242 | $ | 247,691 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Accounts payable, inclusive of the blenders' tax credit rebates due customers of | $ | 10,673 | $ | 10,622 | ||||
| Dividends payable | 2,761 | 10,699 | ||||||
| Other current liabilities | 4,302 | 11,986 | ||||||
| Total current liabilities | 17,736 | 33,307 | ||||||
| Deferred revenue – long-term | 14,453 | 6,324 | ||||||
| Other noncurrent liabilities | 5,345 | 2,239 | ||||||
| Total noncurrent liabilities | 19,798 | 8,563 | ||||||
| Total liabilities | 37,534 | 41,870 | ||||||
| Commitments and contingencies | ||||||||
| Preferred stock, | - | - | ||||||
| Common stock, | 4 | 4 | ||||||
| Additional paid in capital | 203,771 | 205,434 | ||||||
| Retained earnings (accumulated deficit) | (49,067 | ) | 383 | |||||
| Total Stockholders’ Equity | 154,708 | 205,821 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 192,242 | $ | 247,691 | ||||
4
Condensed Consolidated Statements of Operations and Net Income (Dollars in thousands, except per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 19,842 | $ | 61,509 | $ | 95,742 | $ | 243,339 | ||||||||
| Cost of goods sold and distribution | 29,106 | 55,912 | 135,167 | 223,695 | ||||||||||||
| Gross (loss) profit | (9,264 | ) | 5,597 | (39,425 | ) | 19,644 | ||||||||||
| Selling, general, and administrative expenses | 2,538 | 2,796 | 9,699 | 9,279 | ||||||||||||
| Research and development expenses | 687 | 1,190 | 3,866 | 3,993 | ||||||||||||
| Total operating expenses | 3,225 | 3,986 | 13,565 | 13,272 | ||||||||||||
| (Loss) income from operations | (12,489 | ) | 1,611 | (52,990 | ) | 6,372 | ||||||||||
| Interest income | 594 | 1,505 | 3,911 | 7,656 | ||||||||||||
| Other income (expense), net | 35 | (162 | ) | (153 | ) | 2,267 | ||||||||||
| Other income, net | 629 | 1,343 | 3,758 | 9,923 | ||||||||||||
| (Loss) income before income taxes | (11,860 | ) | 2,954 | (49,232 | ) | 16,295 | ||||||||||
| Income tax provision | 151 | 157 | 165 | 792 | ||||||||||||
| Net (loss) income | $ | (12,011 | ) | $ | 2,797 | $ | (49,397 | ) | $ | 15,503 | ||||||
| (Loss) earnings per common share | ||||||||||||||||
| Basic | $ | (0.27 | ) | $ | 0.06 | $ | (1.13 | ) | $ | 0.35 | ||||||
| Diluted | $ | (0.27 | ) | $ | 0.06 | $ | (1.13 | ) | $ | 0.35 | ||||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic | 43,986,765 | 43,773,243 | 43,861,781 | 43,765,757 | ||||||||||||
| Diluted | 43,986,765 | 43,773,243 | 43,861,781 | 43,765,757 | ||||||||||||
5
Consolidated Statements of Cash Flows (Dollars in thousands) (Unaudited) | ||||||||
| Year Ended | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net (loss) income | $ | (49,397 | ) | $ | 15,503 | |||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||||
| Depreciation | 9,657 | 9,208 | ||||||
| Amortization of deferred financing costs | 82 | 103 | ||||||
| (Benefit) provision for deferred income taxes | 137 | 773 | ||||||
| Change in fair value of derivative instruments | (221 | ) | 1,971 | |||||
| Stock based compensation | 1,008 | 359 | ||||||
| (Gain) loss on disposal of property, plant, and equipment | (34 | ) | 30 | |||||
| Noncash interest expense | 36 | 35 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 12,491 | 6,510 | ||||||
| Accounts receivable – related parties | - | 1 | ||||||
| Inventory | (611 | ) | 4,740 | |||||
| Income tax receivable | (35 | ) | 1,887 | |||||
| Prepaid expenses | (99 | ) | 380 | |||||
| Other assets | (4,360 | ) | (146 | ) | ||||
| Accounts payable | (519 | ) | (12,098 | ) | ||||
| Accounts payable – related parties | (99 | ) | 97 | |||||
| Dividends payable | 47 | 186 | ||||||
| Accrued expenses and other current liabilities | (8,506 | ) | 6,324 | |||||
| Deferred revenue | 8,951 | (9,205 | ) | |||||
| Other noncurrent liabilities | 2,737 | (1,856 | ) | |||||
| Net cash (used in) provided by operating activities | (28,735 | ) | 24,802 | |||||
| Cash flows from investing activities | ||||||||
| Collateralization of derivative instruments | (1,388 | ) | (132 | ) | ||||
| Proceeds from the sale of property and equipment | 34 | 6 | ||||||
| Capital expenditures | (17,247 | ) | (14,668 | ) | ||||
| Net cash used in investing activities | (18,601 | ) | (14,794 | ) | ||||
| Cash flows from financing activities | ||||||||
| Payment of dividends | (10,513 | ) | (119,911 | ) | ||||
| Deferred financing costs | (376 | ) | - | |||||
| Net cash used in financing activities | (10,889 | ) | (119,911 | ) | ||||
| Net change in cash and cash equivalents | (58,225 | ) | (109,903 | ) | ||||
| Cash and cash equivalents at beginning of period | 109,541 | 219,444 | ||||||
| Cash and cash equivalents at end of period | $ | 51,316 | $ | 109,541 | ||||
| Cash paid for income taxes | $ | 27 | $ | 457 | ||||
| Cash paid for interest expense | 71 | - | ||||||
| Change in noncash capital expenditures | 669 | 403 | ||||||
6
Reconciliation of Non-GAAP Financial Measure to Financial Measure (Dollars in thousands) (Unaudited) | ||||||||||||||||
| Reconciliation of Adjusted EBITDA to Net Income | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net (loss) income | $ | (12,011 | ) | $ | 2,797 | $ | (49,397 | ) | $ | 15,503 | ||||||
| Depreciation | 2,514 | 2,285 | 9,657 | 9,208 | ||||||||||||
| Non-cash stock-based compensation | 320 | 246 | 1,008 | 359 | ||||||||||||
| Interest income, net | (629 | ) | (1,505 | ) | (3,758 | ) | (7,656 | ) | ||||||||
| Non-cash interest expense and amortization of deferred financing costs | 27 | 35 | 118 | 138 | ||||||||||||
| Loss (gain) on disposal of property and equipment | - | 6 | (34 | ) | 30 | |||||||||||
| Unrealized loss (gain) on derivative instruments | 183 | 531 | (221 | ) | 1,971 | |||||||||||
| Turnaround costs | 964 | 761 | 3,801 | 3,723 | ||||||||||||
| Other expense (income) | 42 | - | 344 | (2,751 | ) | |||||||||||
| Income tax provision | 151 | 157 | 165 | 792 | ||||||||||||
| Adjusted EBITDA | $ | (8,439 | ) | $ | 5,313 | $ | (38,317 | ) | $ | 21,317 | ||||||
| Reconciliation of Adjusted EBITDA to Net Cash Provided by Operating Activities | ||||||||
| Year Ended | ||||||||
| 2025 | 2024 | |||||||
| Net cash (used in) provided by operating activities | $ | (28,735 | ) | $ | 24,802 | |||
| Deferred income taxes, net | (137 | ) | (773 | ) | ||||
| Interest income | (3,758 | ) | (7,656 | ) | ||||
| Income tax provision | 165 | 792 | ||||||
| Changes in operating assets and liabilities, net | (9,997 | ) | 3,180 | |||||
| Turnaround costs | 3,801 | 3,723 | ||||||
| Other expense (income) | 344 | (2,751 | ) | |||||
| Adjusted EBITDA | $ | (38,317 | ) | $ | 21,317 | |||
7
Condensed Consolidated Segment Income (Dollars in thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | ||||||||||||||||
| Custom chemicals | $ | 14,559 | $ | 23,140 | $ | 51,675 | $ | 69,473 | ||||||||
| Performance chemicals | 3,444 | 1,644 | 7,890 | 10,534 | ||||||||||||
| Chemical revenue | 18,003 | 24,784 | 59,565 | 80,007 | ||||||||||||
| Biofuel revenue | 1,839 | 36,725 | 36,177 | 163,332 | ||||||||||||
| Total Revenue | $ | 19,842 | $ | 61,509 | $ | 95,742 | $ | 243,339 | ||||||||
| Segment gross (loss) profit | ||||||||||||||||
| Chemical | $ | (4,532 | ) | $ | 10,527 | $ | (13,007 | ) | $ | 22,632 | ||||||
| Biofuel | (4,732 | ) | (4,930 | ) | (26,418 | ) | (2,988 | ) | ||||||||
| Total gross (loss) profit | $ | (9,264 | ) | $ | 5,597 | $ | (39,425 | ) | $ | 19,644 | ||||||
As of
8
COMPANY CONTACT
(870) 698-5608
www.futurefuelcorporation.com
Source: